Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial

Abstract

Background: The treatment for ineligible transplant multiple myeloma is melphalan prednisone. Curcumin has an anti-inflammatory and antiangiogenesis in cancer-directed to nuclear factor-kappa B (NF-kB) pathway. Interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), and lactate dehydrogenase (LDH) were also involved in the pathogenesis of myeloma. No clinical study has evaluated the efficacy of curcumin in myeloma patients. To evaluate the efficacy of curcumin as adjuvant into melphalan prednisone in myeloma patients

Methods: 33 myeloma patients at Dr. Kariadi General Hospital, Semarang, Indonesia during 2016-2017 were randomly assigned single-blindedly into MPC (n=17) and control group (n=16). The MPC group was treated with melphalan 4 mg/m2, prednisone 40 mg/m2 for 7 days, and curcumin 8 gram daily for 28 days. The MP control group was treated with melphalan, prednisone, and placebo. The primary endpoint was the overall remission. Pre- and post-treatment was examined for NF-κB, VEGF, TNF-α, IL-6, LDH, and CRP levels All data analyses were per protocol.

Results: There was a significant difference in overall remission between the MPC and MP control groups [75% vs 33.3%, x²=6.89, P=0.009]. A significant decrease of NF-κB, VEGF, TNF-α levels were shown in the MPC group compared with the MP control group. There was a significant decrease in IL-6 levels in a subgroup analysis of the MPC group. TNF-α levels had a significant correlation with remission [OR=1.35; (95%CI=1.03-1.76); P=0.03].

Conclusion: Curcumin has an efficacy in improving overall remission and decreasing NF-κB, VEGF, TNF-α, and IL-6 levels in myeloma patients.

Keywords: Myeloma, Overall remission, NF-κB, VGEF, IL-6, TNF-α.

Citation: Santosa D, Suharti C, Riwanito I, et al. Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial. Caspian J Intern Med 2022; 13(2):375-384.

Multiple myeloma (MM) is the 2nd most common hematologic malignancy after lymphoma with an estimated 24,280 to 30,330 new cases and 12,650 deaths with the estimated world-wide 5-year prevalence which is approximately 230,000 patients. (1,2) The therapy varies from chemotherapy, autologous bone marrow transplant (ABMT) until novel agents. (3) Combined complete or partial response rates and the near-complete or complete response rates were 47.6% and 7.2 %, respectively for therapy with melphalan prednisone (MP). The 2-year event-free survival rates were 27% for MP (4). Curcumin is a natural product derived from Curcuma longa, a member of the ginger family, Zingiberaceae. Curcumin has a molecular weight of 368.4, with the molecular structure of C21H20O6. In Indonesia, curcumin is very famous used as one of the spices and also as traditional medicine (5, 6). Curcumin has effect as an anti-inflammatory and anti-tumors as demonstrated in vitro and in vivo studies. Moreover, curcumin affects the progression of myeloma cell (7-11).
This interesting result makes many researchers develop the studies of curcumin as a chemotherapeutic agent. Curcumin has less toxicity and its safety has been approved by the FDA (12). The clinical study of efficacy curcumin has proven to inhibit the progression of monoclonal gammopathy of undetermined significance (MGUS) as well as smoldering multiple myeloma (SMM) (13-15). Curcumin has an anti-inflammatory and anti-angiogenesis in cancer-directed to the target of the NF-κB pathway (16, 17, 18). The other parameters in disease activity and cytokine involved in the pathogenesis of myeloma were IL-6, VEGF, TNF-α, CRP, and LDH (19, 20).

The primary outcome of this study was to prove the efficacy of curcumin in the improvement of the remission in myeloma patients. The secondary outcome was to evaluate the effect of curcumin on transcription factor and cytokine levels, including NF-κB, IL-6, VEGF, TNF-α, CRP, and LDH.

Methods

The study was organized at Dr. Kariadi Hospital, Semarang, Indonesia during 2016-2017. Inclusion criteria were as follows: new MM patients, aged over 18 years old, and ineligible transplant. The exclusion criteria were sepsis, severe infection, pregnancy, patients with severe disease (such as acute hepatitis, chronic hepatitis, cirrhosis) or elevation of aspartate aminotransferase (AST) >3 times upper limit normal (ULN), subjects who participated in another study, and poor performance status. The sample size calculation was 32 participants, a total of 16 patients in each group. The α and β errors chosen for these calculations were 0.05 and 0.2, respectively. The power was 80%. Patients with clinically suspected myeloma were evaluated for full blood count, albumin, globulin, urea, creatinine, calcium, protein electrophoresis, immunotyping, bone survey, bone marrow aspiration, and β-2 microglobulin. The staging was classified according to the International Staging System (ISS). The diagnosis of myeloma was established according to the IMWG 2014 (21, 22).

For the randomization, the participants were randomized into the group with a sealed envelope. A total of 33 patients were allocated randomly in two parallel study groups (Figure 1). The MPC group (17 patients) was treated with MP regimen (melphalan 4mg/m2, prednisone 40mg/2, for 7 days) and curcumin 8 gram /daily for 28 days. The control group (16 patients) was treated with MP regimen and placebo. Oral melphalan, prednisone was taken as a single dose. Curcumin was taken orally – 4 caplets, twice daily. Curcumin 1000 mg (BCM 95, Biocurcem®) is composed of curcuminoid complex 95% and essential oils from turmeric (23) purchased from PT. SOHO Global Health, Indonesia. Each patient was followed up every 28 days, for a total of 4 cycles. The checklist was used for data collection and was filled in each visit separately for every subject. The contents of the checklist were the patients' profiles (age, sex, education level), and laboratory data, including full blood count (FBC), urea, creatinine, NF-κB, IL-6, CRP, LDH, VEGF, and patient group (treatment or control). The physical examination of the patients was performed by a physician in every visit (single blindness). Remission status, NF-κB, IL-6, CRP, LDH, VEGF, and TNF-α were evaluated after the end of the study.

Figure 1. Randomized, single-blind & parallel design of the study. Multiple myeloma patients were single-blindedly randomized to MPC (green) and MP+Placebo (blue) groups. Data collection including full blood count (FBC), urea, creatinine, NF-κB, IL-6, CRP, LDH, VEGF, were collected in the baseline and every cycle (28 days).

Note: R: randomization, MPC: Melphalan dose; 4 mg/m2, Prednisone; 40 mg/m2 (day 1-7); Curcumin dose 8 mg/day (Day 1-28), treatment duration of 1 cycle for 28 days; total treatment 4 cycles; MP: Melphalan + prednisone + placebo
The blood was taken during office hours from the vein and collected in a tube that contains 10 ml EDTA. The blood was centrifuged, then the plasma was collected and kept under -80°C Refrigerator at GAKI Laboratory, UNDIP Semarang. NF-κB, IL-6, VEGF, and TNF-α levels were measured by ELISA following the manufacturer’s instruction in GAKI Laboratory, UNDIP. CRP and LDH levels were measured at Dr. Kariadi Hospital. Protein M serum and FLC were measured in the Cito laboratory and Prodia laboratory, respectively. Complete blood count (CBC) was measured by flow cytometry method (Cell-Dyn Saphire; Abbott Diagnostics Division, Santa Clara, CA, USA). Serum calcium, CRP, and plasma albumin was measured by homogenous enzymatic colorimetric assay (Dade Behring; Siemens, German). Immunofixation electrophoresis is used to identify the clonality (type) of M-proteins measured by agarose gel. NF-κB (p56/total) levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) Kit test, Human. VEGF serum levels were measured by the VEGF ELISA test kit (Quantikine®, Human Soluble VEGF R2 Immunoassay, Catalog Number DVRE 200). IL-6 serum levels were measured by the ELISA kit test (Human IL-6 Immunoassay Catalog Number HS600B). TNF-α serum levels were measured by human TNF-α (ELISA) test kits. The remission was evaluated by bone marrow aspiration, the level of M protein or FLC (free light chain) was classified according to EBMT criteria (for common myeloma type) and IMWG criteria (for light chain myeloma) (24-26).

BCM-95®CG (Biocurcem™) 1000 mg capsules were supplied by Soho Global Health. Biocurcem ™ contains Curruma longa rhizome (Curluminoid complex 95%) with high bioavailability.

Ethical approval and informed consent: This clinical trial has been registered on the ISRCTN registry with study ID ISRCTN14131419. The protocol of the study was approved by the Ethics Committee of the Faculty of Medicine, Diponegoro University, and Dr. Kariadi General Hospital. This study was conducted following the Declaration of Helsinki and all the participants have signed the informed consent.

Statistical Analysis: The analysis within groups was performed using the Friedmann test. The analysis of nominal data between groups was done using the chi-square. The analysis of ratio data between groups was done using Mann-Whitney tests or independent t-test. The ratio data was converted as delta (Δ) by comparison with baseline data. Correlation of variable was done using multiple logistic. The program of SPSS IBM Version 21 was used to analyze the data. The result of the analyzed data was considered significant if p<0.05.

Results

Demography and Characteristics Study: During February 2016 - May 2017, there were 35 myeloma patients in Dr. Kariadi General Hospital, Semarang. Two subjects were excluded from the study. A total number of 33 patients were allocated randomly into two groups. The MPC and MP control groups consist of 17 subjects and 16 subjects, respectively. Four patients in the treatment group died due to sepsis, anemia, and thrombocytopenia in the first-month treatment. Three subjects in the control group died because of sepsis, melena, and anemia in the first-month treatment. One patient from the control group discontinued the study because of flushing after taking medication. One patient in the treatment group was lost of contact in the second month. One patient in the control group died because of anemia and sepsis in the third-month treatment.

Table 1 showed the baseline characteristics of the study population. There were no significant differences in the demographics and characteristics of the study population (age, BMI, creatinine, β2m, albumin, calcium, gender, bone lytic lesions, fractures, myeloma type, anemia, the percentage of the plasma cell, stage, and performance status). The consort of the study was shown in Figure 2.

Effect curcumin in the remission: The overall remission in the MPC group was better than the control. Table 2 showed the overall remission (OR) of myeloma patients treated with melphalan, prednisone, and curcumin increased to 75.0 %, compared with the MP control group of 20.0%. This result was statistically significantly different with p<0.05 (X² = 6.89, df=1, P=0.01). The effect of curcumin in the transcription factor and cytokine levels was shown in table 3. The decrease of NF-κB levels in the MPC group was higher than the MP control group. The table demonstrated the trend of reduction of NF-κB levels that increased in the MPC group. In the 4th month, the reduction of NF-κB levels reached a significant decrease significantly in the MPC group compared with control (0.66 vs-0.05, P=0.027). The trend reduction of IL-6 increased in the MPC group, and was analyzed with the Friedman test. The reduction of IL-6 level showed a significant decrease in the MPC group (P=0.00), not in the MP.
group \((P=0.19)\). However, there was no significant difference between the two groups in IL-6 levels. There was significant decrease of VEGF levels in the MPC group compared with MP control \([(\text{month 1, 100.20 vs 18.87; } P=0.021), (\text{month 2, 76.46 vs -80.82; } P=0.013), (\text{month 3, 76.04 vs 3.89; } P=0.021), (\text{month 4, 187.4 vs -43.38; } P=0.001)}]\). The decrease of VEGF levels in the MPC group was better than the MP control group. The decrease of TNF-\( \alpha \) was higher in the MPC group compared with the MP control group. This reduction of TNF-\( \alpha \) levels was statistically significantly different \((13.7 \text{ vs } 2.07; P=0.004)\). However, there was no significant difference in CRP levels between the MPC and MP control groups. Analysis within-group showed a decrease of CRP levels in both MPC \((P=0.01)\) and MP control group \((P=0.04)\). There was a significant difference in LDH levels between the MPC and control groups. The trend of LDH level increased in the MPC group, but decreased in the control group \((28.77 \text{ vs } 75.41; P=0.008)\).

### Multiple logistic regression:

The variable that correlated with remission with \([P \leq 0.25]\) was included in the multivariate analysis model. Multiple logistic regression analysis showed in Table 4. These data demonstrated the correlation between TNF-\( \alpha \) levels and remission \([\text{OR}=1.35; (95\% CI=1.03-1.76); P=0.03}\).

---

**Figure 2. Consort of study Description:** MPC: melphalan, prednisone, curcumin MP; melphalan, prednisone, placebo. Four patients in the treatment group died because of sepsis, anemia, and thrombocytopenia in the first-month treatment. **Three patients in the control group died because of sepsis, melena, and anemia in the first-month treatment. One patient in the control group stopped taking medication because of flushing. One patient in the treatment group was lost of contact in the second monthly treatment. ***One patient in the control group died because of anemia and sepsis in the third-month treatment.**

---

**Table 1. Demography and Characteristics of the study population**

| Characteristics                  | MPC Group | MP Control Group | \(P\) |
|----------------------------------|-----------|------------------|-------|
| Subject (n=33)                   | 17        | 16               |       |
| Age                              |           |                  |       |
| Mean \(\pm\)                     | 54.88±10.23 | 59.13±9.76       |       |
| Range                            | 36-77     | 31-74            |       |
| Mean Rank                        | 13.9      | 20.3             | 0.58 \(^1\) |
| Creatinine (mg/dL, mean±SD)      | 2.28±1.9  | 1.81±1.2         | 0.46 \(^2\) |
Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial

| Parameter                        | MPC, Melphalan-Prednisone-Curcumin | MP, Melphalan-Prednisone-Placebo | p-value |
|----------------------------------|-------------------------------------|----------------------------------|---------|
| β2 macroglobulin (mcg/L, mean±SD)| 10.78±6.7                           | 13.46±11.0                       | 0.48    |
| Albumin (g/l, mean ±SD)          | 2.7±0.68                            | 2.8±0.79                         | 0.68    |
| Calcium (mmol/l, mean ±SD)       | 2.4±0.59                            | 2.4±0.43                         | 0.73    |
| Sex, [n (%)]                     |                                    |                                  |         |
| Man                              | 12 (70.6)                           | 8 (50.0)                         | 0.23    |
| Woman                            | 5 (29.4)                            | 8 (50.0)                         |         |
| Lytic Lesion of the Bone [n (%)] |                                    |                                  |         |
| Yes                              | 15 (88.2)                           | 16 (100)                         | 0.18    |
| No                               | 2 (11.8)                            | 0                                |         |
| Fracture                         |                                    |                                  |         |
| Yes                              | 5 (29.4)                            | 4 (25)                           | 0.78    |
| No                               | 12 (70.6)                           | 12 (75)                          |         |
| Myeloma Sub-Type [n (%)]         |                                    |                                  |         |
| Immunoglobulin-G                 | 7 (41.2)                            | 7 (43.8)                         | 0.91    |
| Immunoglobulin-A                 | 4 (23.5)                            | 5 (31.3)                         |         |
| Immunoglobulin-M                 | 2 (11.8)                            | 1 (6.3)                          |         |
| Light chain                      | 4 (23.5)                            | 3 (18.8)                         |         |
| Anaemia [n (%)]                  |                                    |                                  |         |
| Creatinine Clearance ≥ 60 ml/min | 7 (41.2)                            | 2 (12.5)                         | 0.07    |
| < 60 ml/min                      | 10 (58.8)                           | 14 (87.5)                        |         |
| Durie-Salmon Staging [n (%)]     |                                    |                                  |         |
| I                                | 0                                  | 0                                | 0.17    |
| II                               | 3 (17.6)                            | 0                                |         |
| IIIA                             | 6 (35.3)                            | 9 (56.3)                         |         |
| IIIB                             | 8 (47.1)                            | 7 (43.8)                         |         |
| International Staging System [n (%)] |                                    |                                  |         |
| I                                | 1 (5.9)                             | 1 (6.3)                          | 0.99    |
| II                               | 1 (5.9)                             | 1 (6.3)                          |         |
| III                              | 15 (88.2)                           | 13 (81.3)                        |         |
| Hypercalcemia [cut point=2.55mmo/L; n (%)] |                                    |                                  |         |
| Yes                              | 7 (41.2)                            | 3 (18.8)                         | 0.20    |
| No                               | 10 (58.8)                           | 12 (75)                          |         |
| Performance Status (ECOG) * [n (%)] |                                    |                                  | 0.45    |
| 0                                | 8 (66.7)                            | 4 (33.3)                         |         |
| 1                                | 3 (25.0)                            | 4 (33.3)                         |         |
| 2                                | 0                                  | 2 (16.7)                         |         |
| 3                                | 1 (8.3)                             | 2 (16.7)                         |         |
| Haemoglobin (g/dl, mean±SD)      | 9.00±2.06                           | 8.32±2.27                        | 0.31    |
| Plasma cell (pg/dl,mean ±SD)     | 36.88±25.19                         | 29.50±11.1=87                    | 0.50    |
| NF-κB(pg/dl, mean±SD)            | 1.67±2.12                           | 0.73±1.10                        | 0.04    |
| IL-6 (pg/dl, mean±SD)            | 27.16±23.69                         | 20.87±23.85                      | 0.29    |
| CRP (mg/l,mean±SD)               | 1.33±1.35                           | 1.23±2.18                        | 0.21    |
| LDH (U/l±mean±SD)                | 481.86±818.15                       | 363.71±144.50                    | 0.63    |
| VEGF (pg/dl, mean±SD)            | 387.39±245.3                        | 245.99±309.99                    | 0.03    |
| TNF-α (pg/dl, mean±SD)           | 22.05±11.11                         | 19.90±9.33                       | 0.67    |

Note 1) Mann-Whitney U Test, 2) Independent T-Test, 3) Chi-Square Test

“Eastern Cooperative Oncology Group”; NF-κB, “Nuclear Factor kappa B”; IL-6, “Interleukin-6”; CRP, “C-reactive protein”; LDH, “Lactic Acid Dehydrogenase”; VEGF, “Vascular endothelial Growth Factor”; TNF-α, “Tumor Necrosis Factor-α”
Table 2. Effect of Curcumin in the remission

|                | MPC group | MP Control | Total |
|----------------|-----------|------------|-------|
| Overall remission | Number    | 9          | 4     | 13   |
| % on treatment group | (75%)     | (33.3%)    | 54.2% |
| Stable disease | Number    | 3          | 8     | 11   |
| % on treatment group | (25.0%)   | (66.7%)    | 45.8% |
| Total           | Number    | 12         | 12    | 24   |

Note: Chi-Square, (X² = 6.89, df=1, \( p=0.01 \))

Abbreviation: MPC, Melphalan-Prednisone-Curcumin; MP, Melphalan-Prednisone-Placebo

Table 3. Effect of curcumin in the transcription factor and cytokine levels

| Variable | Month | Level of transcription factor and cytokine (Δ) | \( p \) |
|----------|-------|-----------------------------------------------|-------|
|          |       | MCP group                                     | MP control |
| NF-κB (pg/dL) | 1     | 0.0795                                        | 0.0947 | 0.149 | δ |
|          | 2     | 0.4654                                        | 0.0468 | 0.133 |
|          | 3     | 0.1294                                        | -0.0584 | 0.525 |
|          | 4     | 0.6636                                        | -0.0508 | 0.027 |
| IL-6 (pg,dL) | 1     | 2.13                                          | 8.50   | 0.326 | δ,φ |
|          | 2     | 13.91                                         | 9.68   | 0.954 |
|          | 3     | 13.99                                         | 6.40   | 0.149 |
|          | 4     | 19.46                                         | 8.30   | 0.176 |
| VEGF (pg/dL) | 1     | 100.20                                        | 18.87  | 0.021 | δ |
|          | 2     | 76.46                                         | -80.82 | 0.013 |
|          | 3     | 76.04                                         | 3.89   | 0.021 |
|          | 4     | 187.40                                        | -43.38 | 0.001 |
| TNF-α (pg/dL) | 4     | 13.07                                         | 2.07   | 0.004 | δ |
| CRP (mg/L) | 1     | 0.74                                          | 0.81   | 0.557 | δ,φ |
|          | 2     | 0.62                                          | 0.30   | 0.074 |
|          | 3     | 0.20                                          | -0.31  | 0.309 |
|          | 4     | 0.63                                          | 0.55   | 0.929 |
| LDH (U/L) | 1     | 202.94                                        | 36.71  | 0.736 | δ |
|          | 2     | 220.76                                        | 66.81  | 0.986 |
|          | 3     | 143.36                                        | 30.13  | 0.157 |
|          | 4     | 128.77                                        | 75.41  | 0.008 |

Note: δ Mann Whitney U Test; φ Friedman Test; IL-6 levels (MPC group \( P=0.00 \), MP group \( P=0.19 \)), CRP levels (MPC (\( P=0.01 \)) and MP group (\( P=0.04 \)) MPC, Melphalan-Prednisone-Curcumin; MP, Melphalan-Prednisone-Placebo; NF-κB, “Nuclear Factor kappa B”; IL-6, “Interleukin-6”; CRP, “C-reactive protein”; LDH, “Lactic Acid Dehydrogenase”; VEGF, “Vascular endothelial Growth Factor”; TNF-α, “Tumor Necrosis Factor-α”

Table 4. Multivariate Analysis of Curcumin, LDH, VEGF, TNF-α on Remission Status

| Step 1 | Variable | \( \text{Coefficient (β)} \) | \( SE \) | \( \text{Wald} \) | \( P \) | OR | 95% CI | \( R^2 \) |
|--------|----------|----------------|------|-------------|-----|-----|-------|-------|
|        | Curcumin | -1.135         | 1.94 | 0.34        | 0.56 | 0.3 | 0.01-14.33 | 0.70 |
|        | VEGF     | -0.003         | 0.01 | 0.01        | 0.64 | 0.42 | 1.00-1.00 | 0.09 |
|        | LDH      | 0.384          | 0.26 | 3.18        | 0.08 | 1.5 | 0.96-1.02 | 0.15 |
|        | TNF-α    | -0.034         | 0.03 | 1.73        | 0.19 | 0.9 | 1.15-457.7 | 0.70 |
|        | Constant | 6.658          | 6.09 | 1.20        | 0.27 | 0.77 | 0.00-1.00 | 0.69 |

| Step 2 | Variable | \( \text{Coefficient (β)} \) | \( SE \) | \( \text{Wald} \) | \( P \) | OR | 95% CI | \( R^2 \) |
|--------|----------|----------------|------|-------------|-----|-----|-------|-------|
|        | VEGF     | -0.004         | 0.01 | 1.12        | 0.29 | 0.1 | 0.99-1.00 | 0.69 |
|        | LDH      | 0.306          | 0.15 | 4.40        | 0.04 | 1.4 | 1.02-1.81 | 0.00 |
|        | TNF-α    | -0.025         | 0.02 | 2.00        | 0.16 | 1   | 0.94-1.01 | 0.00 |
|        | Constant | 4.353          | 4.19 | 1.08        | 0.30 | 0.77 | 0.00-1.00 | 0.00 |

| Step 3 | Variable | \( \text{Coefficient (β)} \) | \( SE \) | \( \text{Wald} \) | \( P \) | OR | 95% CI | \( R^2 \) |
|--------|----------|----------------|------|-------------|-----|-----|-------|-------|
|        | TNF-α    | 0.297          | 0.14 | 4.69        | 0.03 | 1.4 | 1.03-1.76 | 0.64 |
|        | LDH      | -0.027         | 0.02 | 2.73        | 0.10 | 1   | 0.94-1.01 | 0.00 |
Discussion

This study proved that there was a difference in overall remission between the MPC and control groups, significantly. The group treated with curcumin has better outcome than the control according to this remission status. Curcumin effects increase overall remission of 75%. Previous studies showed that myeloma patients who took melphalan prednisone had a low overall response rate of less than 50%, with CR below 5% (27, 28). To the best of our knowledge, this is the first report that demonstrated that curcumin has an effect in increasing overall remission in myeloma patients.

Curcumin has anti-inflammatory and anti-cancer effects. Curcumin interferes with multiple cell signaling pathways, including cell cycle (cyclin D1 and cyclin E), apoptosis proliferation (HER-2, EGFR, and AP-1), survival (PI3K/AKT pathway), invasion (MMP-9 and adhesion molecules), angiogenesis (VEGF), metastasis (CXCR-4) and inflammation (NF-κB, TNF, IL-6, IL-1, COX-2, and 5-LOX).

Curcumin suppressed initiation, progression, angiogenesis, and metastasis of a variety of tumors. The activity of curcumin has been reported against leukemia, lymphoma, gastrointestinal cancers, genitourinary cancers, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, melanoma, neurological cancers, and sarcoma (29-31). Monoclonal gammopathy of undefined significance (MGUS) and smoldering multiple myeloma (SMM) has a risk of progression to multiple myeloma. The preliminary results showed that patients taking curcumin, paraprotein serum drops between 5% and 30% compared with patients on placebo. Curcumin consumption has the potential risk to slow progression in both MGUS and SMM (13, 32) (13)’(32). Curcumin also affects decreasing transcription factor, NF-κB. Treatment with curcumin downregulated the expression of NF-κB. Previous studies revealed that curcumin has anti-inflammatory, its activity was induced by various pathways including TNF-α (11, 30, 32, 33). This study revealed that curcumin affects in decreasing NF-κB level after 4 cycles of treatment and the remission of myeloma patient has a correlation with TNF-α levels.

Numerous studies reported that IL-6 promotes the survival and proliferation of multiple myeloma (MM) cells through the phosphorylation of a cell-signaling protein, STAT3 (19). Interleukin-6 (IL-6) is a cytokine for the defense against acute environmental stress. The pathology in various inflammation and autoimmune disease was caused by persistent dysregulation of IL-6 production diseases(34). Myeloma is a malignancy that is a chronic inflammatory disease (35), it means there is dysregulation of IL-6. This study revealed the decrease of IL-6 level in the group with curcumin. In myeloma patient, the overall survival was significantly different between the low IL-6 and high IL-6 groups, and IL-6 level correlates with the clinical feature and prognosis(36).

The angiogenic activators important in malignancies are vascular endothelial growth factor (VEGF). VEGF has an impact on developing the new vessel in tumors called neovascularization. The new drug was developed against VEGF like bevacizumab approved by US Federal Drug Administration (37, 38). Our study showed that curcumin affects decreasing VEGF levels. In this study, we found that curcumin has activities against TNF-α. Previous reports described that curcumin can block the action and production of TNF-α (17). TNF-α is very important in the pathophysiology of human multiple myeloma(39). TNF-α is also highly expressed in tumors and is thought to be pro-angiogenic cytokine. Paradoxically, at it is in higher doses can be used to destroy tumor vascular (37). TNF-α regulates the tumor environment and it has a pleiotropic effect as a cytokine in the process of apoptosis, angiogenesis, inflammation, and immunity(40).

This study showed, that curcumin does not affect decreasing CRP and LDH levels. C-reactive protein (CRP) was the acute inflammation in interacting with the complement system. These proteins increase in inflammation process and are associated with various diseases including hypertension, atherosclerosis, peripheral vascular disease, diabetes, and metabolic disease (41). The level of serum CRP has an association with the number of osteolytic bone lesions (42). The study reported that curcumin has anti-inflammatory through a significant reduction of IL-6, hs-CRP, and MDA levels (42), not CRP. A high level of serum LDH is a poor prognostic factor in patients with malignancies(43). LDH is a useful marker progression in myeloma(44), but also is found in high levels after physical activities. In Chinese elderly patients with myeloma, LDH has an unfavorable prediction for the outcome (45). Curcumin affects the decreasing NF-κB, IL-6, VEGF, and TNF-α levels. Curcumin improves overall remission in myeloma patient. Multivariate analysis proved

| Constant | 4.363 | 3.99 | 1.19 | 0.28 | 78.4 |

Note: multiple logistic regression, VEGF, “Vascular endothelial growth factor”; LDH, “Lactic dehydrogenase”; TNF-α, “Tumor necrosis factor-α”
that TNF-α correlates with remission. This study revealed that curcumin improves remission through decreasing TNF-α level. Previous studies demonstrated that curcumin affected the transcription and angiogenic factors especially TNF-α.

In conclusion the addition of curcumin in myeloma patients treatment with MP regimen will improves the overall remission. Curcumin affects the decrease of NF-kB, IL-6, VEGF, and TNF-α levels. A future study is needed to evaluate the effects of curcumin to the survival and effect of curcumin in combination with another novel agent.

Acknowledgments

I would like thank the following: Prof Hertanto WS, MD, Ph.D., and Suhartono MD, PhD for statistical analysis. M.I Tjahjati Djoko M, MD (Head of GAKI Laboratory), Prodia Laboratory, and Cito Laboratory Semarang for laboratory analysis. Prof. Aru W Sudojo, MD, Ph.D., Prof Lisyani BS, MD, Moedrik ST, MD, PhD for the preparation of this research protocol and final analysis. Prof. Tri Nur Kristina, MD, Ph.D, as Dean of Faculty of Medicine Diponegoro University and Fifin Lutfia R, MD, PhD, Director Post Graduate Program of Faculty Medicine, Diponegoro University.

Funding: This project got partial funding from LPDP, Ministry of Finance of the Republic of Indonesia.

Conflicts of Interests: The authors have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject discussed in this manuscript.

Data availability statement

The data used to support the findings of this study are restricted by the Ethics Committee of the Faculty of Medicine, Diponegoro University, and Dr. Kariadi Hospital and available on request from the corresponding author, (DS). The data are not publicly available due to the information that could compromise the privacy of the research participant.

References

1. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66: 443–59.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
3. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91: 101–19.
4. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367: 825–31.
5. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: The Indian solid gold. Adv Exp Med Biol 2007; 595: 1–75.
6. Subositi S, Wahyono S. Study of The Genus Curcuma in Indonesia used as traditional herbal medicines. Biodiversitas 2019; 20: 1356-61.
7. Sung B, Kunnumakkara AB, Sethi G, et al. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8: 959–70.
8. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053–62.
9. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013; 15: 195–218.
10. Fang BM, Jiang JH, Zhang XW, et al. Curcumin enhances bortezomib treatment of myeloma by inhibiting heat shock protein 90 expression. Trop J Pharm Res 2015; 14: 227–33.
11. Aggarwal BB. Anticancer potential of curcumin. Anticancer Res 2003; 23: 363-98.
12. Hewlings S, Kalman D. Curcumin: A review of its’ effects on human health. Foods 2017; 6: 92.
13. Golombick T, Diamond T. The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemina. Biol Targets Ther 2008; 2: 161–3.
14. Vermorken AJM, Zhu J, Van de Ven WMJ, Andrés E. Curcumin for monoclonal gammopathies. What can we hope for, what should we fear? Crit Rev Oncol Hematol 2012; 84: 350–60.
15. Golombick T, Diamond TH, Badmaev V, Manoharan A,
Ramakrishna R. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance - Its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 2009; 15: 5917–22.

16. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in IFN-α-sensitive and IFN-α-resistant human bladder cancer cells. Mol Cancer Ther 2007; 6: 1022–30.

17. Aggarwal BB, Gupta SC, Sung B. Curcumin: An orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 2013; 169: 1672–92.

18. Sciberras JN, Galloway SD, Fenech, A, et al. The effect of turmeric (Curcumin) supplementation on cytokine and inflammatory marker responses following 2 hours of endurance cycling. J Int Soc Sports Nutr 2015; 12: 5.

19. Bharti AC, Donato N, Aggarwal BB. Curcumin (Diferuloylmethane) inhibits constitutive and IL-6-Inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863–71.

20. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008; 57: 1509–17.

21. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1545–56.

22. Chng WJ, Dispensieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269–77.

23. Antony B, Merina B, Iyer V, et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax™), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 2008; 70: 445–9.

24. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–73.

25. Kyle RA, Rajkumar V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.

26. Ludwig H, Durie BGM, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012; 119: 3003–15.

27. Harousseau JL. Induction therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2008: 2008:306-12.

28. Bladé J, Cibeira MT, Rosiñol L. Novel drugs for the treatment of multiple myeloma. Haematologica 2010; 95: 702–4.

29. Anand P, Sundaram C, Jhurani S, Kunnunakkara AB, Aggarwal BB. Curcumin and cancer: An ‘old-age’ disease with an ‘age-old’ solution. Cancer Lett 2008; 267: 133–64.

30. Shanmugam MK, Rane G, Kanchi MM, et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules 2015; 20: 2728–69.

31. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009; 41: 40–59.

32. Zaidi A, Lai M, Cavenagh J. Long-term stabilisation of myeloma with curcumin. BMJ Case Rep 2017; 2017: bcr2016218148.

33. Gilmore TD. Multiple myeloma: lusting for NF-κB. Cancer Cell 2007; 12: 95–7.

34. Tanaka T, Kishimoto T. Targeting interleukin-6: All the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012; 8: 1227–36.

35. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med 2006; 79: 123–30.

36. Xing LJ, Xu Y, An G, et al. Prognostic value of serum IL-6 in patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013; 21: 1492–5.

37. Burton ER, Libutti SK. Targeting TNF-α for cancer therapy. J Biol 2009; 8: 85.

38. Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: Responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2012; 2: a006593.

39. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor a in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519–27.

40. Ham B, Fernandez MC, D’Costa Z, Brodt P. The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res 2016; 11: 1–27.

41. Ingle PV, Patel DM. C-reactive protein in various disease
condition - an overview. Asian J Pharm Clin Res 2011; 4: 9–13.

42. Tarbizi R, Vakili S, Akbari M, et al. The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. Phytother Res 2019; 33: 253-62.

43. Liu R, Cao J, Gao X, et al. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L. Tumor Biol 2016; 37: 14083–8.

44. Teke HÜ, Başak M, Teke D, Kanbay M. Serum level of lactate dehydrogenase is a useful clinical marker to monitor progressive multiple myeloma diseases: a case report. Turk J Hematol 2014; 31: 84–7.

45. Gu Y, Yuan YH, Xu J, et al. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. Oncotarget 2017; 8: 48350–61.